Company intelligence / Profile preview
Tonglu Biopharmaceutical
Hangzhou, Zhejiang, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Tonglu Biopharmaceutical is a China-based biotechnology company focused on the development of innovative therapeutics for metabolic diseases, particularly type 2 diabetes and obesity. The company specializes in the research and development of GLP-1 receptor agonists and other metabolic modulators. Its lead programs aim to provide effective and convenient treatment options for patients with chronic metabolic conditions. Tonglu Biopharmaceutical operates research and manufacturing facilities in Hangzhou, leveraging local expertise in biopharmaceutical production.
- Therapeutic areas
- Endocrinology
- Modalities
- Small moleculeRecombinant protein
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Tonglu Biopharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tonglu Biopharmaceutical.